Literature DB >> 31230945

Structural Basis of CD160:HVEM Recognition.

Weifeng Liu1, Sarah C Garrett1, Elena V Fedorov1, Udupi A Ramagopal1, Scott J Garforth1, Jeffrey B Bonanno1, Steven C Almo2.   

Abstract

CD160 is a signaling molecule that interacts with herpes virus entry mediator (HVEM) and contributes to a wide range of immune responses, including T cell inhibition, natural killer cell activation, and mucosal immunity. GPI-anchored and transmembrane isoforms of CD160 share the same ectodomain responsible for HVEM engagement, which leads to bidirectional signaling. Despite the importance of the CD160:HVEM signaling axis and its therapeutic relevance, the structural and mechanistic basis underlying CD160-HVEM engagement has not been described. We report the crystal structures of the human CD160 extracellular domain and its complex with human HVEM. CD160 adopts a unique variation of the immunoglobulin fold and exists as a monomer in solution. The CD160:HVEM assembly exhibits a 1:1 stoichiometry and a binding interface similar to that observed in the BTLA:HVEM complex. Our work reveals the chemical and physical determinants underlying CD160:HVEM recognition and initiation of associated signaling processes.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  CD160 and HVEM; IgSF and TNFRSF interactions; Interaction promiscuity; T cell costimulation and coinhibition; X-ray structures; immune regulation; intermolecular beta-sheet

Mesh:

Substances:

Year:  2019        PMID: 31230945      PMCID: PMC7477951          DOI: 10.1016/j.str.2019.05.010

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  52 in total

1.  Inference of macromolecular assemblies from crystalline state.

Authors:  Evgeny Krissinel; Kim Henrick
Journal:  J Mol Biol       Date:  2007-05-13       Impact factor: 5.469

2.  Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells.

Authors:  S Agrawal; J Marquet; G J Freeman; A Tawab; P L Bouteiller; P Roth; W Bolton; G Ogg; L Boumsell; A Bensussan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

3.  [20] Processing of X-ray diffraction data collected in oscillation mode.

Authors:  Zbyszek Otwinowski; Wladek Minor
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  Decoy strategies: the structure of TL1A:DcR3 complex.

Authors:  Chenyang Zhan; Yury Patskovsky; Qingrong Yan; Zhenhong Li; Udupi Ramagopal; Huiyong Cheng; Michael Brenowitz; Xiao Hui; Stanley G Nathenson; Steven C Almo
Journal:  Structure       Date:  2011-02-09       Impact factor: 5.006

5.  Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition.

Authors:  Katie M Stiles; J Charles Whitbeck; Huan Lou; Gary H Cohen; Roselyn J Eisenberg; Claude Krummenacher
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

6.  Experimental phasing with SHELXC/D/E: combining chain tracing with density modification.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

Authors:  Haidong Tang; Yang Wang; Lukasz K Chlewicki; Yuan Zhang; Jingya Guo; Wei Liang; Jieyi Wang; Xiaoxiao Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

8.  CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.

Authors:  John R Šedý; Ryan L Bjordahl; Vasileios Bekiaris; Matthew G Macauley; Brian C Ware; Paula S Norris; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  J Immunol       Date:  2013-06-12       Impact factor: 5.422

9.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

10.  Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.

Authors:  Yuwen Zhu; Sheng Yao; Mathew M Augustine; Haiying Xu; Jun Wang; Jingwei Sun; Megan Broadwater; William Ruff; Liqun Luo; Gefeng Zhu; Koji Tamada; Lieping Chen
Journal:  Sci Adv       Date:  2016-04-08       Impact factor: 14.136

View more
  11 in total

1.  Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors.

Authors:  Aditya J Basak; Snigdha Maiti; Anita Hansda; Dhrubajyoti Mahata; Kheerthana Duraivelan; Shankar V Kundapura; Woonghee Lee; Gayatri Mukherjee; Soumya De; Dibyendu Samanta
Journal:  J Mol Biol       Date:  2020-10-05       Impact factor: 5.469

2.  Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer.

Authors:  Lina Wen; Zongqiang Han
Journal:  J Gastrointest Oncol       Date:  2021-12

3.  Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.

Authors:  Rojan Shrestha; Sarah C Garrett-Thomson; Weifeng Liu; Steven C Almo; Andras Fiser
Journal:  Structure       Date:  2020-08-13       Impact factor: 5.006

Review 4.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

5.  Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.

Authors:  Katarzyna Kuncewicz; Claire Battin; Adam Sieradzan; Agnieszka Karczyńska; Marta Orlikowska; Anna Wardowska; Michał Pikuła; Peter Steinberger; Sylwia Rodziewicz-Motowidło; Marta Spodzieja
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

6.  Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome.

Authors:  Annabelle Small; Suzanne Cole; Jing J Wang; Sunil Nagpal; Ling-Yang Hao; Mihir D Wechalekar
Journal:  J Clin Med       Date:  2022-01-21       Impact factor: 4.241

7.  HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.

Authors:  Weifeng Liu; Ting-Fang Chou; Sarah C Garrett-Thomson; Goo-Young Seo; Elena Fedorov; Udupi A Ramagopal; Jeffrey B Bonanno; Qingyang Wang; Kenneth Kim; Scott J Garforth; Kiyokazu Kakugawa; Hilde Cheroutre; Mitchell Kronenberg; Steven C Almo
Journal:  J Exp Med       Date:  2021-10-28       Impact factor: 14.307

8.  PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.

Authors:  Lingling Bao; Kai Sun; Xuede Zhang
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

Review 9.  On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function.

Authors:  Éva S Vanamee; Denise L Faustman
Journal:  Cells       Date:  2020-03-20       Impact factor: 6.600

Review 10.  Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways.

Authors:  Jiaxin Liu; Yicheng Cheng; Ming Zheng; Bingxiao Yuan; Zimu Wang; Xinying Li; Jie Yin; Mingxiang Ye; Yong Song
Journal:  Signal Transduct Target Ther       Date:  2021-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.